Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The Role of CD44 in Disease Pathophysiology and Targeted Treatment
This review focuses both CD44-hyaluronan dependent and independent CD44 signaling and the role of CD44–HA interaction in various pathophysiologies and the recent advances in novel treatment strategies that exploit the CD44 –HA interaction either for direct targeting or for drug delivery. Expand
Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.
- Soum D. Lokeshwar, Benjamin T. Harper, +5 authors Z. Klaassen
- Translational andrology and urology
- 1 October 2019
A narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection. Expand
Targeting hyaluronic acid family for cancer chemoprevention and therapy.
Basic and clinical translational aspects of targeting each HA family member and respective treatment approaches that have been described in the literature are discussed. Expand
Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets
- Daley S Morera, Martin S Hennig, +14 authors V. Lokeshwar
- British Journal of Cancer
- 3 October 2017
This study demonstrates that the HA family can be exploited for developing a biomarker-driven, targeted treatment for bladder cancer, and 4MU, a non-toxic oral HA synthesis inhibitor, is one such candidate. Expand
Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA.
Molecular subtypes reflect bladder tumor heterogeneity and associate with tumor-grade and in multiple cohorts/subtyping-classifications, clinical parameters outperform subtypes for predicting outcome. Expand
Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer
It is delineates that sHA-F targets tumor-associated HA-HAase system and could be potentially useful in BCa treatment and inhibited tumor growth in 253J-L and HT1376 xenograft models. Expand
Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer.
- T. Yates, Luis E. Lopez, +6 authors V. Lokeshwar
- Biology, Medicine
- Journal of the National Cancer Institute
- 1 July 2015
4-MU is an effective nontoxic, oral chemopreventive, and therapeutic agent that targets PCa development, growth, and metastasis by abrogating HA signaling. Expand
A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.
- Andrew Mitchell, Sarrah L. Hasanali, +13 authors V. Lokeshwar
- Cancer biomarkers : section A of Disease markers
Results of 451 specimens from both cohorts reveal that the CXCR-4/7+CXCL-12 signature potentially predicts outcome in CRC patients and may allow earlier intervention. Expand
Molecular targeting of renal cell carcinoma by an oral combination
This study highlights how targeting specific mechanisms that cause the failure of “old” modestly effective FDA-approved drugs could improve treatment response with minimal alteration in toxicity profile. Expand
Promotion of epithelial hyperplasia by interleukin‐8—CXCR axis in human prostate
- Diandra K. Smith, Sarrah L. Hasanali, +8 authors B. Lokeshwar
- Chemistry, Medicine
- The Prostate
- 16 June 2020
This work evaluated the expression of inflammatory cytokines in clinical specimens, primary cultures, and prostatic lineage cell lines to investigate whether IL‐8 via its receptor system (IL‐8 axis) promotes BPH. Expand